Strides Pharma Science’s arm gets USFDA’s approval for EET tablets

04 Oct 2023 Evaluate

Strides Pharma Science’s step?down wholly owned subsidiary -- Strides Pharma Global has received approval for Efavirenz (600mg), Emtricitabine (200mg), Tenofovir Disproxil Fumurate (300mg) (EET) tablets from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Atripla Tablets of Gilead Sciences LLC. The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products.

The EET tablet has a market opportunity in the US of around $7.5 million per IQVIA. The product will be manufactured at the company’s facility in Bengaluru. The PEPFAR approval for Strides qualifies the Company to participate in global donor funded programs that procure this lifesaving medicine and it is supplied in around 10 countries. As of full year 2022, donor procurement for EET Tablets is estimated at a value of around $15 million. This product further strengthens the available offerings in HIV treatment from Strides.

The company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which more than 230 ANDAs have been approved. The company has set a target to launch around 60 new products over three years in the US.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

679.95 -4.35 (-0.64%)
23-Dec-2024 10:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1814.00
Dr. Reddys Lab 1351.00
Cipla 1476.25
Lupin 2170.00
Zydus Lifesciences 974.20
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.